A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint BlockadeLivnat Jerby‐Arnon, Charles H. Yoon, David Liu et al.|Cell|2018Cited by 1.5k
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Mouhammed Amir Habra, Funda Meric‐Bernstam et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 130
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in MelanomaShelly Kalaora, Yardena Samuels, Yochai Wolf et al.|Cancer Discovery|2018Cited by 100
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunityPatricia Ho, Benjamin Izar, Johannes C. Melms et al.|Cancer Cell|2023Cited by 93
A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating LymphocytesMarie-Andrée Forget, Chantale Bernatchez|Frontiers in Immunology|2017Cited by 55